BRIEF—Korean companies announce antibody deal

South Korean biopharma company Celltrion has announced a joint research and development agreement with Genuv, a Seoul-based biotech.

Korean media reported on the deal on Tuesday, revealing that the companies will collaborate on discovering up to two antibodies using Genuv's ‘shine mouse’ antibody discovery platform and engage in joint R&D.

According to Korea Biomedical Review, if Celltrion exercises its license-in option based on the results of the joint study, the development milestone per antibody case will be up to 33 billion won ($25 million). If the cumulative sales after commercialization reach 10 trillion won, up to 900 billion won will be payable in sales milestones to Genuv.